Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 30, 2022 - Issue 7-8
Submit an article Journal homepage
300
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma

Ryan T. Yanagiharaa Department of Ophthalmology, University of Washington, Seattle, Washington, USA
, MD,
Elysse S. Toma Department of Ophthalmology, University of Washington, Seattle, Washington, USA
, MD,
Gerami D. Seitzmanb Department of Ophthalmology, Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA
, MD &
Steven S. Sarafa Department of Ophthalmology, University of Washington, Seattle, Washington, USACorrespondence[email protected]
, MD
Pages 2005-2009 | Received 28 Feb 2021, Accepted 06 May 2021, Published online: 19 May 2021

References

  • Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–1888. doi:10.1056/NEJMoa1406037.
  • Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–636. doi:10.1056/NEJMoa1904059.
  • Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703. doi:10.1056/NEJMoa1210093.
  • van der Noll R, Leijen S, Neuteboom GHG, Beijnen JH, Schellens JHM. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013;39(6):664–672. doi:10.1016/j.ctrv.2013.01.003.
  • Sarny S, Neumayer M, Kofler J, El-Shabrawi Y. Ocular toxicity due to trametinib and dabrafenib. BMC Ophthalmol. 2017;17(1):146. doi:10.1186/s12886-017-0541-0.
  • Mozo Cuadrado M, Tabuenca Del Barrio L, Compains Silva E. Bilateral drug-induced uveitis and epiretinal membrane during the treatment of a metastatic cutaneous melanoma. Ocul Immunol Inflamm: 1–3. Published online November 22, 2019.
  • Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735–737. doi:10.1111/1346-8138.14273.
  • Lim J, Lomax AJ, McNeil C, Harrisberg B. Uveitis and papillitis in the setting of dabrafenib and trametinib therapy for metastatic melanoma: a case report. Ocul Immunol Inflamm. 2018;26(4):628–631. doi:10.1080/09273948.2016.1246666.
  • Albertini GC, Corbelli E, Battaglia Parodi M, Bandello F. Choroidal neovascularization in multifocal choroiditis after dabrafenib and trametinib. Eur J Ophthalmol. 2017;27(6):e184–e186. doi:10.5301/ejo.5001013.
  • Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer. 2016;65:130–138. doi:10.1016/j.ejca.2016.06.018.
  • Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol. 2016;27(6):998–1005. doi:10.1093/annonc/mdw100.
  • Schoenberger SD, Kim SJ. Bilateral multifocal central serous-like chorioretinopathy due to MEK inhibition for metastatic cutaneous melanoma. Case Rep Ophthalmol Med. 2013;2013:673796. doi:10.1155/2013/673796.
  • Messersmith WA, Falchook GS, Fecher LA, et al. Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer. J Clin Orthod. 2011;29(4_suppl):246.
  • Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25(7):1437–1441. doi:10.1093/annonc/mdu169.
  • Tyagi P, Santiago C. New features in MEK retinopathy. BMC Ophthalmol. 2018;18(Suppl 1):221. doi:10.1186/s12886-018-0861-8.
  • Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect. 2015;5(1):17. doi:10.1186/s12348-015-0049-9.
  • Woltsche N, Kruger MA, Weger M, Wolf IH, Seidel G. Intravitreal steroid treatment for uveitis associated with dabrafenib and trametinib for metastatic cutaneous melanoma. Ocul Immunol Inflamm. 2020:1–3. Published online January 6. doi:10.1080/09273948.2019.1695860.
  • Niro A, Recchimurzo N, Sborgia A, Guida M, Alessio G. Bilateral ischemic retinal vasculitis in metastatic cutaneous melanoma patient treated with dabrafenib and trametinib: a case report. Ocul Immunol Inflamm. 2018;26(5):783–785. doi:10.1080/09273948.2016.1261166.
  • Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol. 2014;158(4):831–837.e2. doi:10.1016/j.ajo.2014.07.003.
  • Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–615. doi:10.1016/S1470-2045(18)30142-6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.